Free tool
FAERS Monitor: Modeyso
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219876 or its brand name (Modeyso, Dordaviprone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
129
Serious
97
75% of reports
Hospitalization
27
Death reported
72
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death60
- fatigue15
- disease progression11
- nausea10
- neoplasm progression9
- seizure7
- vomiting7
- constipation6
- hospitalisation6
- off label use6
- product dose omission issue6
- headache5
- hydrocephalus5
- muscular weakness5
- asthenia4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 30 |
| 2026 | 99 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,030 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hydrocephalusSignal | 5 | 149.8 | 63.4 | 597 |
| neoplasm progressionSignal | 9 | 42.2 | 22.5 | 323 |
| disease progressionSignal | 11 | 15.2 | 8.6 | 132 |
| deathSignal | 60 | 11.4 | 9.4 | 580 |
| seizureSignal | 7 | 9.9 | 4.8 | 48 |
| muscular weaknessSignal | 5 | 7.2 | 3.0 | 21 |
| hospitalisationSignal | 6 | 6.4 | 2.9 | 22 |
| constipationSignal | 6 | 4.5 | 2.1 | 13 |
| product dose omission issueSignal | 6 | 3.3 | 1.5 | 8 |
| fatigueSignal | 15 | 3.1 | 2.0 | 21 |
| vomitingSignal | 7 | 2.4 | 1.2 | 5 |
| nauseaSignal | 10 | 2.1 | 1.1 | 5 |
| asthenia | 4 | 1.7 | 0.7 | 1 |
| headache | 5 | 1.3 | 0.6 | 0 |
| off label use | 6 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.